News Acceleron axes clinical development of muscular dystrophy dr... Acceleron has axed clinical development of its ACE-083 in the inherited muscle-wasting disease muscular dystrophy, after the drug fell short against efficacy measures in a phase 2 trial.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
